09:55 AM EST - Spectral Diagnostics Inc. : announced it has entered into agreements for a non-brokered private placement of up to $18.2 million. The Corporation intends to use the net proceeds of the Proposed Offering to fund its EUPHRATES clinical development program for PMX, its lead theranostics product for the treatment of severe sepsis with septic shock and for working capital and general corporate purposes. Spectral Diagnostics Inc.
shares T.SDI are trading unchanged at $0.32.
